11.21.17
Industrial bioscience company Amyris, Inc. said it sold its Brazilian production facility to Royal DSM.
The companies established a long-term manufacturing partnership for Amyris's high-volume products.
The consideration for Amyris Brasil Ltda, which owns and operates the Brotas 1 production facility, and intellectual property related to farnesene, a bio-based key intermediate, is $58 million plus an additional value share arrangement over a three-year period amounting to $37.5 million
DSM will continue existing supply-agreements to Amyris and other parties. DSM will also supply Amyris with specialty compounds until it realizes its Brotas 2 specialties production facility. Amyris is accelerating the construction of its second facility dedicated to specialty products while maintaining the manufacturing process development and business support capability located in Campinas, Brazil.
Subject to customary conditions, the transaction is expected to close in the next few months.
The strategic alliance between DSM and Amyris started in May 2017 with an equity investment by DSM in Amyris, and has since been expanded with several significant product development collaborations.
The sale of the Brotas 1 facility, which was designed to produce high volumes of farnesene, together with the creation of a long-term production relationship for high-volume farnesene-based intermediates will enable Amyris to focus on its core strength of developing breakthrough bioscience technologies through a portfolio approach that continues to target key markets, as well as the production of specialty products.
“Our know-how in fermentation, downstream process development and large-scale manufacturing will allow us to further improve the operational performance of the facility while further strengthening our strategic alliance with Amyris”, said DSM Nutritional Products President and CEO Chris Goppelsroeder.
“We are building a specialty plant at Brotas (Brotas 2) and also expect to complete our São Martinho plant to focus on sweeteners,” said Amyris President and CEO John Melo. “The combination of these actions provides us the manufacturing footprint to meet our current demand through the next 3-5 years and to manage this within our funding constraints.”
The companies established a long-term manufacturing partnership for Amyris's high-volume products.
The consideration for Amyris Brasil Ltda, which owns and operates the Brotas 1 production facility, and intellectual property related to farnesene, a bio-based key intermediate, is $58 million plus an additional value share arrangement over a three-year period amounting to $37.5 million
DSM will continue existing supply-agreements to Amyris and other parties. DSM will also supply Amyris with specialty compounds until it realizes its Brotas 2 specialties production facility. Amyris is accelerating the construction of its second facility dedicated to specialty products while maintaining the manufacturing process development and business support capability located in Campinas, Brazil.
Subject to customary conditions, the transaction is expected to close in the next few months.
The strategic alliance between DSM and Amyris started in May 2017 with an equity investment by DSM in Amyris, and has since been expanded with several significant product development collaborations.
The sale of the Brotas 1 facility, which was designed to produce high volumes of farnesene, together with the creation of a long-term production relationship for high-volume farnesene-based intermediates will enable Amyris to focus on its core strength of developing breakthrough bioscience technologies through a portfolio approach that continues to target key markets, as well as the production of specialty products.
“Our know-how in fermentation, downstream process development and large-scale manufacturing will allow us to further improve the operational performance of the facility while further strengthening our strategic alliance with Amyris”, said DSM Nutritional Products President and CEO Chris Goppelsroeder.
“We are building a specialty plant at Brotas (Brotas 2) and also expect to complete our São Martinho plant to focus on sweeteners,” said Amyris President and CEO John Melo. “The combination of these actions provides us the manufacturing footprint to meet our current demand through the next 3-5 years and to manage this within our funding constraints.”
